BioCryst Pharmaceuticals, Inc.

4505 Emperor Blvd.
North Carolina
United States

Tel: 919-859-1302

Show jobs for this employer

About BioCryst Pharmaceuticals, Inc.

BioCryst uses state-of-the-art structure-guided drug design, which incorporates multiple scientific disciplines including biology, crystallography, medicinal chemistry and computer modeling, in order to most efficiently develop new therapeutic candidates. In December 2014, RAPIVAB® was approved by the FDA, the first U.S. approval for a BioCryst discovered drug.

BioCryst's current pipeline consists of the following development programs:

  • Oral inhibitors of plasma kallikrein for hereditary angioedema; BCX7353 and other 2nd generation candidates
  • BCX4430 a broad spectrum antiviral for development as a medical countermeasure against hemorrhagic fevers

Drug Development is a Journey.  Watch BioCryst pushing forward for Hereditary Angioedema (HAE) patients.

440 articles with BioCryst Pharmaceuticals, Inc.